Mirtazapin Beta (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2 and 5‑HT3 receptors. This dual action enhances both noradrenergic and serotonergic neurotransmission, contributing to its antidepressant effect.

The specific dose of Mirtazapin Beta is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions precisely.

Safety data for mirtazapine in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtazapin Beta (mirtazapine) belongs to the NaSSA class, differing from SSRIs and SNRIs by its receptor profile. It often provides stronger sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Store Mirtazapin Beta at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mirtazapin Beta is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis or severe neutropenia, seizures, severe hypersensitivity reactions, and the emergence or worsening of suicidal thoughts, especially during early treatment or dose changes. Patients should be monitored closely for these events.

Mirtazapin Beta should be avoided in patients with known hypersensitivity to mirtazapine or any excipients, those currently taking monoamine oxidase inhibitors, and individuals with severe hepatic impairment unless specifically advised by a physician.